Get the latest news, insights, and market updates on LMAT (LeMaitre Vascular, Inc.). Explore the news page 1 on MyTopStock.com for investor discussions, analysis, and real-time stock performance coverage.
3 Russell 2000 Stocks Walking a Fine Line
The Russell 2000 (^RUT) is home to many small-cap stocks, offering investors the chance to uncover hidden gems before the broader market catches on. However, these companies often come with higher volatility and risk, as their smaller size makes them more vulnerable to economic downturns. Nov 14, 2025 - $LMAT
5 Must-Read Analyst Questions From LeMaitre’s Q3 Earnings Call
LeMaitre’s third quarter results drew a negative market reaction as revenue trailed Wall Street expectations, despite solid year-over-year growth. Management cited strong performances from the Grafts and Shunts product lines as key contributors, with organic sales growth driven primarily by price increases rather than unit volume. CEO George LeMaitre pointed out that a recall earlier in the year led some customers to pull forward purchases, limiting Q3 and likely Q4 growth. International expansi Nov 13, 2025 - $LMAT
LeMaitre to Participate in Upcoming Investor Conferences
BURLINGTON, Mass., Nov. 12, 2025 (GLOBE NEWSWIRE) -- LeMaitre Vascular, Inc. (Nasdaq:LMAT) announced today that management will participate in three upcoming investor conferences. Jefferies London Healthcare Conference 2025 Tuesday, November 18, 2025Waldorf Hilton, LondonDorian LeBlanc, CFO, will present at 8:00 AM GMT Wolfe Research 7th Annual Healthcare Conference Wednesday, November 19, 2025Wolfe NYC Offices, New York, NYDavid Roberts, President, will present at 10:40 AM ET Piper Sandler 37th Nov 12, 2025 - $LMAT
LMAT Q3 Deep Dive: Pricing and Margin Expansion Offset by Cautious Growth Outlook
Medical device company LeMaitre Vascular (NASDAQ:LMAT) missed Wall Street’s revenue expectations in Q3 CY2025, but sales rose 11.4% year on year to $61.05 million. Next quarter’s revenue guidance of $62.8 million underwhelmed, coming in 2.9% below analysts’ estimates. Its GAAP profit of $0.75 per share was 31.5% above analysts’ consensus estimates. Nov 7, 2025 - $LMAT
LeMaitre Vascular (LMAT) Q3 Earnings Surpass Estimates
LeMaitre (LMAT) delivered earnings and revenue surprises of +8.77% and -2.03%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock? Nov 7, 2025 - $LMAT
We use cookies and similar technologies to collect and process data such as browsing activity or unique identifiers.
Selecting "Allow All" lets us enhance your experience and provide personalized content and ads.
Choosing "Essential Cookies Only" enables only the cookies necessary for core site functions, such as staying logged in.
For more information, please see our Privacy Policy.
Continue with Google
Continue with Facebook
Continue with Microsoft
Continue with Apple